Current Clinical Studies and registry trials
Helping Make a Difference
Agendia’s extensive clinical trials and research collaborations have produced numerous retrospective and prospective validation studies over the past decade further supporting the prognostic and predictive ability of MammaPrint and BluePrint for early stage breast cancer patients. In addition, large, multi-institutional clinical trials, such as MINDACT and ISPY-2, can be expected to expand the assay’s clinical importance and indications for use. In the first ever prospective, observational study for a breast cancer recurrence assay, the five year prospective results of the RASTER study were published indicating that chemotherapy may be safely withheld in MammaPrint identified Low Risk breast cancer patients. The Low Risk patient group, which primarily chose to forego chemotherapy, had a 97% distant recurrence free interval (DRFI) at 5 years. Published studies continue to support the strong prognostic and predictive clinical utility of Agendia’s genomic assays and ongoing large, multi-site clinical trials seek to expand clinical indications for use.